Bormioli Pharma issues a binding offer to acquire GCL Pharma Srl

Bormioli Pharma announces the issuing of a Binding Offer for the acquisition of 100% of GCL Pharma, an Italian subsidiary of the Guala Closures Group, specialised in the production of plastic, rubber and aluminium closures for pharmaceutical applications.

In 2019 GCL Pharma recorded a turnover of approximately 8 M€. Over the years the company has demonstrated strong innovation capabilities by continuously improving its product range to meet the most stringent pharma standards. The company main premises and production plant are located in Vasto (Chieti).

The aggregate purchase price offered for the acquisition is 8,9 M€.

“With the acquisition of GCL Pharma, we will continue our growth path. – says Andrea Lodetti, CEO of Bormioli Pharma – We aim to strengthen our industrial footprint by adding new technologies that allow to extend our product range, especially in the oral and parenteral segments, activating further business synergies”.

Marco Giovannini, Group Chairman and CEO of Guala Closure Group commented: “This disposal will allow the Guala Closures Group to fully-focus on its core business, and specifically on high value closures with increased growth prospective, including connected closures”.

Closing of the transaction is expected in the next few weeks.

About Bormioli Pharma

Bormioli Pharma operates in close partnership with the pharmaceutical industry and with all the businesses that are engineering the future of healthcare. As a world-renowned player in the packaging industry, Bormioli Pharma serves the pharmaceutical and biopharmaceutical market with integrated glass and plastic containers, closures, and packaging accessories using state-of-the-art materials and technologies.
Each product is a unique combination of rigorous studies, cutting-edge technology, extreme testing, advanced industrial processes, and the finest materials.

As a partner to the pharmaceutical industry, Bormioli Pharma invests and innovates with one goal in mind: improving people’s lives. Bormioli Pharma employees over 1200 people, produces 6.5 billion pieces every year and had an annual turnover of approximately €250 million in 2019.

Guala Closures Group

Guala Closures Group has more than 4,700 employees and operates in 5 continents through 30 production plants and markets its products in over 100 countries. Today the Group sells nearly 20 billion closures yearly, with a 2019 turnover of 607 million Euros. Thanks to a policy of continuous business development and technological innovation, the Group is recognized as a global point of reference in the production of alcohol safety closures and is a leading manufacturer of aluminium closures for spirits, wines and beverages.

From August 2018, Guala Closures S.p.A. has been listed on the STAR segment of the Italian Stock Exchange, entering the FTSE Italia Mid Cap index in September 2019. Find out more on www.gualaclosures.com

‏